- Home
- FDMT vs BBNX Comparison
FDMT vs BBNX Comparison
Compare FDMT & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDMT | BBNX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 515.6M | 493.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | FDMT | BBNX |
|---|---|---|
| Price | $9.49 | $12.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $31.71 | $24.78 |
| AVG Volume (30 Days) | 783.4K | ★ 1.0M |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | $70.28 | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $2.89 | $8.80 |
| 52 Week High | $12.34 | $32.71 |
Technical Indicators
Market Signals| Indicator | FDMT | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 63.38 |
| Support Level | $8.41 | $12.48 |
| Resistance Level | $9.78 | $15.53 |
| Average True Range (ATR) | 0.64 | 0.86 |
| MACD | -0.01 | 0.38 |
| Stochastic Oscillator | 41.98 | 97.65 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.